Slide 1: InspireMD MGuard: A stent solution for the heart attack market
InspireV“D MGUARD A stent solution that addresses an/unmet need in the heart attack market September 2011
Slide 2: Forward-Looking Statements
Forward-Looking Statements tains “forwarc-looking ‘words"intends, expects," “anticipates, ‘potenti similar wards. Forward-looking statements are nat guarantees of future performance, are based on certain assumptions and are subject ta various known and unknown risks and uncertainties, many of which
Slide 3: The Problem: Heart Attacks (Acute MI) Can Be Deadly
The Problem: Heart Attacks (Acute MI) Can Be Deadly =. Emboli ogee: Debris goes down stream closing tiny arteries 3 inspireMD
Slide 4: Competition Neglects Huge and Growing Market
Competition Neglects Huge and Growing Market: KO Ke MGuard’s Target Market e Inadequate outcome as Current stents were designed primarily for the Stable Angina population e Favorable growth demographics Developing countries Stable Increase in awareness Angina Stable Angina (Chest Pain) Mature market
Slide 5: Embolic protection
Embolic protection - Safer procedures by filtering plaque and debris Spreads struts pressure - Reduces injury Identical deliverability to other stents Excellent endothelization ae 4 | Growing acceptance | by physicians 7 faspirelD
Slide 6: MGuard clinical trials: 586 patients
MAGICAL, Dariusz Dudek, Poland ao ¥" Federico Pisdone, Italy aes Ajay, Roshan Weerackody, UK oe 208 ry, GB Danzi, Italy First in Man, Eberhard Grube, Germany 41 # Alexandre Abizaid, So Paulo, Brazil 30 Eugenio Martuscelli, Italy 22 @ Hana Vaknin-Assa, Ran Kornowski , Israel 41 # Varshitzky, Boguslav
Slide 7: MGuard Acute MI/STEMI patients vs. BMS/DES/Aspiration
MGuard 414 Acute MI/STEMI patients vs. BMS/DES/Aspiration in ~5000 AMI patients in historical trials x2 x18 x80 35.2% 27.5% a} x 17.2% 37.3% avGt ri MGuard| 0-1 os 3 000s Blush Grade a stone predictor fr adverse events” * CONTROL, AVG 6 Trials, N=5124, caou.s6, roRzoNs, TAPAS, EXPORT, EXPIRA,REMMEDI
Slide 8: Major Adverse Cardiac Events
42.1 = oe x1. 1 43.5, 10.2% ax | f MGuard ase ave Woes 2% ave mcuard Mauard 1 mont 6 months 1 sear 0.005 P<005 Major Adverse Cardiac Events > CONTROL, AVGE Trials N5124 =-HorizonsTrial DES ARM, N=2257 Horizons Trial (AVG BMS & DES Outcome) 8 “77 MGuard, N=414, , meta-analysis Company and investigato
Slide 9: MASTER and FDA trial designs
Enrollment Start-End Objective Primary End Points Secondary End Points Follow Up Population Chairman, Pls Status MASTER TRIAL 93/2011 — 92/2012 Superiority over BMS andDES in achieving better myocardial reperfusion 21% increase in frequency of complete ST resolution from 60% to 73% Blush, TIMI, 30d;
Slide 10: Inspire Intellectual Property, Patents (pending)
Inspire Intellectual Property, 10 Patents (pending) ia | e First patent priority date: May 2005 ““yex,, @ Initial filing: PCT, US, e Stent Platform has US freedom to operate legal opinion IP protects key attributes of mesh technology: 1 Anchoring Drug Macro delivery structure width for excellent 10
Slide 11: MGuard Positioning
MGuard Positioning Price: ~Drug Eluding Stent Majority of cases: Acute Coronary Syndromes MGuard is becoming a 34 Tool Creates viable stent option for heart attacks Actual European catheter lab cabinet and stent inventory "1 inspireMD
Slide 12: Building on InspireMD's Platform Technology
Building on InspireMD’'s Platform Technology. Product Addressable Approval Stage Candidate Market MGuard + $2.38 Launched in Europe, South America, MGuard Prime : nd, its . CE Mark by Carotid MGuard $3.0B => pao > Peripheral MGuard $1.08 —_> DrugEludingMesh $5.5 —_> Cerebral Aneurisms $1.08 —_> 2 in
Slide 13: US Launch
US LAUNCH Initiate MASTER MASTER trial Trial Primary endpoint ® inspire
Slide 14: Management team
14 ceo fir Pa, MSEEMMEA, “Proven entrepreneur with sttong track record of creating shareholder value “CEO and Founder of Peach Networks, saoquired by Miracoftin 2000 ‘Headed Micresot TV Platform Group in israel from 2000-2002 ‘Director of several high tech and medioal Startup companies sinoe 2002 “D
Slide 15: NSPR.OB common stock listed on OTCBB
- NSPR.OB common stock listed on OTCBB - Private Placement Mar-Apr 2011 - 74MM shares at $1.50 » 3.7 MM warrants at $1.80 exercise price » $8.4 MM cash balance* - 64.2MM shares outstanding* *As of June30, 2011 Fully diluted share count is 81.1 MM including warrants 15 faspirelD
Slide 16: Addressing the $2.3B Acute MI Market
Addressing the $2.3B | *~2M patients/yr, high risk, un-met need, + limited competition Acute Ml Market + Favorable demographics for growth ® Great Adaptation + CE Mark Approved +~20,000 (2/2011) stents sold, ~15,000 deployed in First World countries +Encouraging outcomes compared to the industry @ P
Slide 17: Thank You
17 Thank You inspireMD